Abstract
Objective In this large multi-institutional study, we aimed to analyze the prognostic power of computed tomography (CT)-based radiomics models in COVID-19 patients.
Methods CT images of 14,339 COVID-19 patients with overall survival outcome were collected from 19 medical centers. Whole lung segmentations were performed automatically using a previously validated deep learning-based model, and regions of interest were further evaluated and modified by a human observer. All images were resampled to an isotropic voxel size, intensities were discretized into 64-binning size, and 105 radiomics features, including shape, intensity, and texture features were extracted from the lung mask. Radiomics features were normalized using Z-score normalization. High-correlated features using Pearson (R2>0.99) were eliminated. We applied the Synthetic Minority Oversampling Technique (SMOT) algorithm in only the training set for different models to overcome unbalance classes. We used 4 feature selection algorithms, namely Analysis of Variance (ANOVA), Kruskal- Wallis (KW), Recursive Feature Elimination (RFE), and Relief. For the classification task, we used seven classifiers, including Logistic Regression (LR), Least Absolute Shrinkage and Selection Operator (LASSO), Linear Discriminant Analysis (LDA), Random Forest (RF), AdaBoost (AB), Naïve Bayes (NB), and Multilayer Perceptron (MLP). The models were built and evaluated using training and testing sets, respectively. Specifically, we evaluated the models using 10 different splitting and cross-validation strategies, including different types of test datasets (e.g. non-harmonized vs. ComBat-harmonized datasets). The sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve (AUC) were reported for models evaluation.
Results In the test dataset (4301) consisting of CT and/or RT-PCR positive cases, AUC, sensitivity, and specificity of 0.83±0.01 (CI95%: 0.81-0.85), 0.81, and 0.72, respectively, were obtained by ANOVA feature selector + RF classifier. In RT-PCR-only positive test sets (3644), similar results were achieved, and there was no statistically significant difference. In ComBat harmonized dataset, Relief feature selector + RF classifier resulted in highest performance of AUC, reaching 0.83±0.01 (CI95%: 0.81-0.85), with sensitivity and specificity of 0.77 and 0.74, respectively. At the same time, ComBat harmonization did not depict statistically significant improvement relevant to non-harmonized dataset. In leave-one-center-out, the combination of ANOVA feature selector and LR classifier resulted in the highest performance of AUC (0.80±0.084) with sensitivity and specificity of 0.77 ± 0.11 and 0.76 ± 0.075, respectively.
Conclusion Lung CT radiomics features can be used towards robust prognostic modeling of COVID-19 in large heterogeneous datasets gathered from multiple centers. As such, CT radiomics-based model has significant potential for use in prospective clinical settings towards improved management of COVID-19 patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Swiss National Science Foundation under grant SNRF 320030_176052.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by institutional review boards (IRBs) of Shahid Beheshti University of Medical Sciences, Alborz University of Medical Sciences and Tehran University of Medical Sciences, Iran, and written informed consent of patients was waived by the ethics committees as anonymized data were used without any interventional effect on diagnosis, treatment or management of COVID-19 patients
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript